Methylprednisolone Addition in IVF Treatment of Infertile Couples
NCT ID: NCT01220791
Last Updated: 2010-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
130 participants
INTERVENTIONAL
2009-01-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Follicular Medrol
In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
In vitro fertilization treatment for infertility
IVF treatment
No medrol group
Patients will receive only Antagonist protocol for IVF as usual
In vitro fertilization treatment for infertility
IVF treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
In vitro fertilization treatment for infertility
IVF treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
36 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioGenesis
INDUSTRY
HRG
UNKNOWN
Universitair Ziekenhuis Brussel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HRG
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Basil Tarlatzis, Professor
Role: STUDY_CHAIR
BioGenesis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biogenesis
Thessaloniki, Pylaia, Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Bider D, Menashe Y, Goldenberg M, Dulitzky M, Lifshitz A, Dor J. Dexamethasone as an adjuvant therapy for anovulatory, normoandrogenic patients during ovulation induction with exogenous gonadotropins. J Assist Reprod Genet. 1996 Sep;13(8):613-6. doi: 10.1007/BF02069638.
Related Links
Access external resources that provide additional context or updates about the study.
web page of investigator centre
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Medrol005
Identifier Type: -
Identifier Source: org_study_id